• Revenue and guidance: Dr Lal PathLabs reported its highest quarterly revenue in four years with 19% year-on-year growth, raising its FY27 growth guidance to mid-teens from early teens. Sample volumes grew about 11% while patient volumes rose approximately 8%.
• Realization drivers: Total realization improved by 8% to 10%, supported by a 6% to 7% underlying gain from test and geography mix and an additional 2% to 3% tailwind from CGHS and ECHS price hikes.
• Margin outlook: Despite delivering a 31% EBITDA margin in Q1, full-year guidance is maintained at 27% to 28% to fund growth investments, with potential for an upward revision after H1 results.
• Inorganic expansion: Armed with approximately ₹1,690 crore in cash, the company is evaluating strategic acquisition opportunities to strengthen brand presence in South India and Gujarat.